{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T08:14:24Z","timestamp":1783671264721,"version":"3.55.0"},"reference-count":22,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Measurable residual disease Partnership and Alliance in Acute myeloid leukemia Clinical Treatment (MPAACT) Consortium"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Personalized Medicine"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/17410541.2026.2682844","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T08:34:52Z","timestamp":1780907692000},"page":"227-234","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Toward a harmonized assessment of MRD by NGS: blinded pilot study of NGS assays by MPAACT consortium"],"prefix":"10.1080","volume":"23","author":[{"given":"Vanessa","family":"Obourn","sequence":"first","affiliation":[{"name":"Novartis","place":["Cambridge, USA"]},{"name":"Bristol Myers Squibb","place":["Cambridge, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalaka","family":"Patel","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Madison, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Lopez","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Summit, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hersey","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Madison, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stern","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb","place":["Lawrenceville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habib","family":"Hamidi","sequence":"additional","affiliation":[{"name":"Genentech-Roche","place":["South San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013626"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-801498"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01692-0"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4600"},{"key":"e_1_3_7_8_1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines). Acute myeloid leukemia. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.09.020"},{"key":"#cr-split#-e_1_3_7_10_1.1","unstructured":"U.S. Food and Drug Administration. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment. Guidance for industry 2020 [updated 2020"},{"key":"#cr-split#-e_1_3_7_10_1.2","unstructured":"cited 2025 May 13]. Available from: https:\/\/www.fda.gov\/media\/117035\/download"},{"key":"#cr-split#-e_1_3_7_11_1.1","unstructured":"U.S. Food and Drug Administration. Acute myeloid leukemia: developing drugs and biological products for treatment guidance for industry. 2022 [updated October 2022"},{"key":"#cr-split#-e_1_3_7_11_1.2","unstructured":"Oct [cited 2025 May 13]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/acute-myeloid-leukemia-developing-drugs-and-biological-products-treatment-0"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00412"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01126-3"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000676"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-829911"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01131-6"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716863"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11020252"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283520"},{"key":"e_1_3_7_20_1","unstructured":"Horizon. OncoSpan gDNA cited 13 May 2025]. Available from: https:\/\/horizondiscovery.com\/en\/reference-standards\/products\/oncospan-gdna"},{"key":"e_1_3_7_21_1","unstructured":"SeraCare. Seraseq\u00ae myeloid mutation DNA mix cited 13 May 2025]. Available from: https:\/\/www.seracare.com\/Seraseq-Myeloid-Mutation-DNA-Mix-0710-0408\/"},{"key":"e_1_3_7_22_1","unstructured":"European Medicines Agency. Letter of support for measurable residual disease (MRD) as a surrogate efficacy endpoint in clinical studies with acute myeloid leukemia. EMADOC-1700519818-1285629. 2024 Feb 15 [cited 2025 May 13]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/letter-support-measurable-residual-disease-mrd-surrogate-efficacy-endpoint-clinical-studies-acute-myeloid-leukemia_en.pdf"}],"container-title":["Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17410541.2026.2682844","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17410541.2026.2682844","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17410541.2026.2682844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:30:41Z","timestamp":1783668641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17410541.2026.2682844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/17410541.2026.2682844"],"URL":"https:\/\/doi.org\/10.1080\/17410541.2026.2682844","relation":{},"ISSN":["1741-0541","1744-828X"],"issn-type":[{"value":"1741-0541","type":"print"},{"value":"1744-828X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}